New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
09:00 EDTXOMAXOMA Phase III gevokizumab trial likely to miss endpoint, says Summer Street
Summer Street believes Xoma's Phase III trial for gevokizumab will likely not meet the primary endpoint of being effective in treating eye involvement in patients with BehÁetís disease. The firm says prior clinical trials indicate that the product is only a weak anti-inflammatory agent.
News For XOMA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
07:19 EDTXOMAXOMA CFO Fred Kurland to retire, Thomas Burns to succeed
XOMA announced Thomas Burns, vice president, Finance, will succeed Fred Kurland as CFO when Kurland retires from his role as vice president, Finance, CFO and Secretary effective April 3. Burns joined the XOMA finance team in 2006.
February 24, 2015
07:31 EDTXOMARBC Capital to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use